Company / Capital Expenditures
10x Genomics, Inc. Capital Expenditures History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$5.9M
FY2025
5-year range
$5.9M / $131.7M
FY2021-FY2025
Trend
-52.1%
vs FY2024
Sector context
#122 of 145
Health Care
What the data says
10x Genomics, Inc.'s capital expenditures of $6M is lower than 84% of companies in the Health Care sector (FY2025). Capital Expenditures has declined for 3 consecutive years, from $132M in FY2022 to $6M in FY2025.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of -30.5%.
Declined from $49M to $6M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -64.4%
- 5-Year CAGR
- -30.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 145This company $5.9M Sector average $268.6M
▼
-97.8% below sector average
Key checks
Key Insights
- 10x Genomics, Inc.'s capital expenditures has declined for 3 consecutive years.
- 5-year CAGR of -30.5%, indicating a declining trend.
- In FY2025, capital expenditures decreased 52.1% year-over-year.
- Ranks #122 out of 145 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.9M | -52.1% |
| FY2024 | $12.4M | -74.5% |
| FY2023 | $48.6M | -63.1% |
| FY2022 | $131.7M | +30.0% |
| FY2021 | $101.3M | +176.2% |
| FY2020 | $36.7M | -14.2% |
| FY2019 | $42.7M | +580.2% |
| FY2018 | $6.3M | +67.3% |
| FY2017 | $3.8M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026